Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen.

Shilpa Vishwanath, Fuad M Baroody, Mohamad R Chaaban, Marcella deTineo, Kenneth H Lasser, Elliot C Lasser, Robert M Naclerio

Journal: The Journal of allergy and clinical immunology 2011;128(1):219-21

PMID: 21414657

Full Text on Elsevier Science View on PubMed

Abstract

DOI: 10.1016/j.jaci.2011.02.024

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Administration, Intranasal, Allergens, Anti-Allergic Agents, Cross-Over Studies, Double-Blind Method, Humans, Ioxaglic Acid, Nasal Provocation Tests, Rhinitis, Allergic, Seasonal, Sneezing

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.